title: Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia.
abstract: Screening for primary hyperaldosteronism (PHA) is often indicated in individuals with resistant hypertension or hypokalaemia. However, in the far larger subset of the hypertensive population who do not fit into these criteria, the evidence for screening is conflicting and dependent on the disease prevalence. The purpose of this study was to examine the prevalence of PHA in a large population with mild to moderate hypertension and without hypokalaemia using a carefully controlled study protocol including a normotensive control population. Hypertensive subjects underwent medication washout and both hypertensive and normotensive subjects placed on a high-sodium diet prior to biochemical and haemodynamic testing. Study specific cutoff values were based on results from the normotensive population studied under identical conditions. A screening test (serum aldosterone/PRA ratio [ARR]>25 with a serum aldosterone level >8 ng/dl) was followed by a confirmatory test (urine aldosterone excretion rate [AER] >17 microg/24 h) to demonstrate evidence of PHA. An elevated ARR with a concomitant elevated serum aldosterone was present in 26 (7.5%) individuals. Of these, 11 (3.2%) had an elevated AER, consistent with evidence of PHA. Individuals with PHA had higher blood pressure and lower serum potassium levels while on a high-sodium diet. Sodium restriction neutralized these differences between PHA and essential hypertensives. The prevalence of PHA in this mild to moderate hypertensive population without hypokalaemia is at most 3.2%, a rate that might lead to excessive false positives with random screening in comparable populations. Hyperaldosteronism, when present, is responsive to sodium restriction.
authors.affiliation: Department of Medicine, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. Jwilliams5@partners.org
authors.forename: J S
authors.initials: JS
authors.lastname: Williams
authors.forename: G H
authors.initials: GH
authors.lastname: Williams
authors.forename: A
authors.initials: A
authors.lastname: Raji
authors.forename: X
authors.initials: X
authors.lastname: Jeunemaitre
authors.forename: N J
authors.initials: NJ
authors.lastname: Brown
authors.forename: P N
authors.initials: PN
authors.lastname: Hopkins
authors.forename: P R
authors.initials: PR
authors.lastname: Conlin
mesh_terms: D000450:Aldosterone / Q000097:blood / Q000652:urine; D044383:Black People; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000097:blood / Q000150:complications / Q000453:epidemiology* / Q000652:urine; D006973:Hypertension / Q000150:complications*; D007008:Hypokalemia; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D011188:Potassium / Q000652:urine; D012083:Renin / Q000097:blood; D012982:Sodium, Dietary / Q000008:administration & dosage* / Q000652:urine
chemical_list: D012982:Sodium, Dietary; D000450:Aldosterone; D012083:Renin; D011188:Potassium